Find Reports
Select Report Type
Reimbursement Review
Displaying 1376 - 1400 of 1429
Please scroll or swipe to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| mirvetuximab soravtansineOpens in new tab | TBC | mirvetuximab soravtansine | Epithelial ovarian, fallopian tube, or primary peritoneal cancer | Active | PC0394-000 | ||||
| Mantle cell lymphomaOpens in new tab | Mantle cell lymphoma | Active | PH0087-000 | ||||||
| Gastric cancerOpens in new tab | Gastric cancer | Merged | PH0080-000 | ||||||
| Diffuse large B cell lymphoma ...Opens in new tab | Diffuse large B | Open for Input | PH0078-000 | ||||||
| dabrafenib trametinibOpens in new tab | TBC | dabrafenib trametinib | Pediatric low grade glioma (ped LGG) | Active | PX0375-000 | ||||
| Dabrafenib trametinibOpens in new tab | N/A | Dabrafenib trametinib | Head and neck cancer | Active | PX0373-000 | ||||
| abemaciclibOpens in new tab | Verzenio | abemaciclib | HR-positive, HER2-negative advanced or metastatic breast cancer | Active | PC0400-000 | ||||
| lemborexantOpens in new tab | Dayvigo | lemborexant | Insomnia | Active | SR0895-000 | ||||
| letermovirOpens in new tab | Prevymis | letermovir | Cytomegalovirus infection (CMV), prophylaxis | Withdrawn | SR0824-000 | ||||
| vorasidenibOpens in new tab | Voranigo | vorasidenib | Astrocytoma or oligodendroglioma, IDH1 or IDH2 mutation | Received | PC0407-000 | ||||
| pembrolizumabOpens in new tab | Keytruda | pembrolizumab | Advanced or recurrent endometrial carcinoma | Active | PC0383-000 | ||||
| Esophageal or Gastroesophageal...Opens in new tab | Esophageal or Gastroesophageal Junction Cancer | Open for Feedback | PH0061-000 | ||||||
| durvalumab, tremelimumabOpens in new tab | Imfinzi, Imjudo | durvalumab, tremelimumab | Metastatic non-small cell lung cancer (NSCLC) | Active | PC0390-000 | ||||
| durvalumabOpens in new tab | Imfinzi | durvalumab | limited-stage small cell lung cancer (LS-SCLC) | Active | PC0389-000 | ||||
| isatuximabOpens in new tab | Sarclisa | isatuximab | multiple myeloma not eligible for ASCT | Active | PC0378-000 | ||||
| AripiprazoleOpens in new tab | N/A | Aripiprazole | Depression | Active | SX0756-000 | ||||
| mirikizumabOpens in new tab | Omvoh | mirikizumab | Crohn’s disease | Active | SR0880-000 | ||||
| risankizumabOpens in new tab | Skyrizi | risankizumab | Ulcerative colitis | Active | SR0890-000 | ||||
| pembrolizumabOpens in new tab | Keytruda | pembrolizumab | Advanced or metastatic malignant pleural mesothelioma | Active | PC0387-000 | ||||
| daratumumabOpens in new tab | Darzalex SC | daratumumab | Multiple myeloma, eligible for autologous stem cell transplant | Active | PC0388-000 | ||||
| lazertinib and amivantamabOpens in new tab | Lazcluze and Rybrevant | lazertinib and amivantamab | Locally advanced or metastatic non-small cell lung cancer (NSCLC) | Active | PC0392-000 | ||||
| polatuzumab vedotinOpens in new tab | Polivy | polatuzumab vedotin | Large B-cell lymphoma | Active | PC0397-000 | ||||
| leuprolide mesylateOpens in new tab | Camcevi | leuprolide mesylate | Prostate cancer | Active | PC0370-000 | ||||
| belzutifanOpens in new tab | Welireg | belzutifan | advanced renal cell carcinoma (RCC) | Active | PC0386-000 | ||||
| durvalumab, carboplatin, pacli...Opens in new tab | Imfinzi | durvalumab, carboplatin, paclitaxel | Endometrial cancer that is mismatch repair deficient (dMMR) | Active | PC0366-000 |
Health Technology Review
Displaying 601 - 602 of 602
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 26 of 26
View All Reports
Displaying 1376 - 1400 of 2141
Please scroll or swipe to view the full content.
Provisional Funding Algorithm
Displaying 76 - 81 of 81